Inhibition of Herpes Simplex Virus-1 Replication by Natural Compound Honokiol
Honokiol is a pleiotropic natural compound isolated from Magnolia and has multiple biological and clinically relevant effects, including anticancer and antimicrobial function. However, the antiviral activity of honokiol has not yet been well studied. Here we showed that honokiol had no effect on herpes simplex virus-1 (HSV-1) entry, but inhibited HSV-1 viral DNA replication, gene expression and the production of new progeny viruses. The combination of honokiol and clinical drug acyclovir augmented inhibition of HSV-1 infection. Our results illustrate that honokiol could be a potential new candidate for clinical consideration in the treatment of HSV-1 infection alone or combination with other therapeutics.
KeywordsHonokiol Herpes simplex virus-1 (HSV-1) Viral replication Anti-viral activity Acyclovir
We thank Dr. Chunfu Zheng (Fujian Medical University) for providing the HSV-1-GFP virus. This work was supported by the grant from National Key Research and Development Program (2016YFA0502100).
XL conceived and designed the experiments. SL, LL and LT performed the experiments and analyzed the data. XL wrote and finalized the manuscript. All authors read and approved the final manuscript.
Compliance with Ethical Standards
Conflicts of interest
The authors declare that they have no conflict of interest.
Animal and Human Rights Statement
All animal studies were conducted following protocols approved by the Institutional Animal Care and Usage Committee of Institut Pasteur of Shanghai, Chinese Academy of Sciences.
- Andrei G, Topalis D, Fiten P, McGuigan C, Balzarini J, Opdenakker G, Snoeck R (2012) In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol 86:2641–2652CrossRefGoogle Scholar
- Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL (2003) Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278:35501–35507CrossRefGoogle Scholar
- Balfour HH Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A, Klein T, Polsky B, Safrin S (1994) Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 7:254–260Google Scholar
- Hafidh RR, Abdulamir AS, Abu Bakar F, Sekawi Z, Jahansheri F, Jalilian FA (2015) Novel antiviral activity of mung bean sprouts against respiratory syncytial virus and herpes simplex virus -1: an in vitro study on virally infected Vero and MRC-5 cell lines. BMC Complement Altern Med 15:179CrossRefGoogle Scholar
- Jacobo-Salcedo Mdel R, Gonzalez-Espindola LA, Alonso-Castro AJ, Gonzalez-Martinez Mdel R, Dominguez F, Garcia-Carranca A (2011) Antimicrobial activity and cytotoxic effects of Magnolia dealbata and its active compounds. Nat Prod Commun 6:1121–1124Google Scholar
- Kuribara H, Stavinoha WB, Maruyama Y (1999) Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side-effects in mice. J Pharm Pharmacol 51:97–103Google Scholar
- Song JM, Anandharaj A, Upadhyaya P, Kirtane AR, Kim JH, Hong KH, Panyam J, Kassie F (2016) Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. Oncotarget 7:57752–57769Google Scholar
- Tian W, Xu D, Deng YC (2012) Honokiol, a multifunctional tumor cell death inducer. Pharmazie 67:811–816Google Scholar
- Wolf I, O’Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, Arbiser JL, Koeffler HP (2007) Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol 30:1529–1537Google Scholar
- Zhang Q, Zhao W, Ye C, Zhuang J, Chang C, Li Y, Huang X, Shen L, Li Y, Cui Y, Song J, Shen B, Eliaz I, Huang R, Ying H, Guo H, Yan J (2015) Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. Oncotarget 6:37335–37348Google Scholar